Drug Trial Radar · NCT07106827
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
10
Planned (sponsor's estimate)
Start
Sep 4, 2025
Primary completion
Jun 11, 2027
Study completion Jun 11, 2028
Sponsor
- Lead sponsor
- West China HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- GV20 Therapeutics
- First posted
- Aug 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, single-center study for multiple tumor indications to evaluate the safety of GV20-0251. The trial uses a 3 + 3 design and enrolls 3-6 patients in the 10 mg/kg and 20 mg/kg dose groups, respectively. The cancer types include solid tumors.
Conditions
- HCC - Hepatocellular Carcinoma
- Cholangiocarcinoma
- Melanoma
- NSCLC (Non-small Cell Lung Cancer)
- Pancreatic Ductal Adenocarcinoma
- HNSCC
- Endometrial Cancer
- Testicular Cancer
Interventions
GV20-0251Drug
Increasing doses of GV20-0251 administered by intravenous (IV) infusion once every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate GV20-0251 safetyTime frame: From Cycle 1 Day 1 dosing (each cycle is 21 days) until meeting the study termination criteria or 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital
Chengdu, Sichuan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.